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Circulating Tumor Cells
Affi nity Versus Label-Free Isolation of Circulating 
Tumor Cells: Who Wins?
 Vasudha  Murlidhar ,  Lianette  Rivera-Báez ,  and  Sunitha  Nagrath * 
 The study of circulating tumor cells (CTCs) has been 
made possible by many technological advances in their 
isolation. Their isolation has seen many fronts, but 
each technology brings forth a new set of challenges 
to overcome. Microfl uidics has been a key player in 
the capture of CTCs and their downstream analysis, 
with the aim of shedding light into their clinical 
application in cancer and metastasis. Researchers have 
taken diverging paths to isolate such cells from blood, 
ranging from affi nity-based isolation targeting surface 
antigens expressed on CTCs, to label-free isolation 
taking advantage of the size differences between CTCs 
and other blood cells. For both major groups, many 
microfl uidic technologies have reported high sensitivity 
and specifi city for capturing CTCs. However, the 
question remains as to the superiority among these two 
isolation techniques, specifi cally to identify different CTC 
populations. This review highlights the key aspects of 
affi nity and label-free microfl uidic CTC technologies, 
and discusses which of these two would be the highest 
benefactor for the study of CTCs. 
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 1.  Introduction 
 1.1.  Circulating Tumor Cells 
 Emerging evidence has pointed to the importance of circu-
lating tumor cells (CTCs) in the spread of cancers. [ 1 ] CTCs, 
suspected of being precursors of metastasis [ 2 ] have been in 
the spotlight as a liquid biopsy [ 3–6 ] and are being investigated 
as surrogate biomarkers for clinical trials. [ 7–9 ] These are cells 
shed by a primary tumor into the blood circulation, and can 
potentially form secondary tumors en route. [ 10 ] Being inter-
mediaries between the primary and metastatic tumors, they 
offer insights into both; additionally they can reveal key 
aspects of the metastatic cascade. Indeed, there have been 
studies showing that CTCs have distinct identities, consisting 
of a heterogeneous mix of populations similar to both the 
primary tumor and the metastatic tumor. [ 11–14 ] CTCs can be 
detected from the peripheral blood of patients and hold the 
promise of being a real time biomarker for cancer detection 
and management. [ 15 ] The utility of CTCs as a predictive and 
prognostic marker has been explored in various cancers like 
breast cancer, prostate cancer, liver cancer, and colorectal 
cancer. [ 16–19 ] For example, in patients with metastatic breast 
cancer, the number of CTCs before and during treatment 
is an independent predictor of progression free and overall 
survival. [ 18,20 ] Nagrath et al. surveyed patients from different 
cancers in advanced stages over their treatment course and 
showed that changes in CTC numbers could predict changes 
in the tumor burden. [ 21 ] Elevated CTC numbers during treat-
ment have also been shown to be associated with disease 
progression. [ 20,22 ] Furthermore, it is possible to monitor treat-
ment-resistant mutations and telomerase activity in CTCs, 
thereby demonstrating their clinical utility in therapeutic 
monitoring. [ 23,24 ] 
 The current gold standard for CTC isolation is the Cell-
Search (Veridex, USA) system, which is the only FDA 
approved system for CTC detection. [ 19 ] This test separates 
epithelial cells using magnetic beads functionalized with 
antibodies against the epithelial cell adhesion molecule 
(EpCAM). [ 25 ] Using the CellSearch system it has been 
shown that CTCs have prognostic utility in breast, prostate, 
and colon cancers. [ 19 ] However, there is considerable cell 
loss (≈20%–40%) caused by the inability of the platform to 
detect cancer cells with a reduced EpCAM expression, such 
as those that have gone through or are in the process of going 
through epithelial to mesenchymal transition (EMT). [ 26,27 ] 
Currently, CTC studies are geared toward fi nding genetic sig-
natures that could guide treatment decisions. [ 28 ] 
 The major challenge toward accomplishing more with 
these entities lies in their rarity; CTCs are detected at a fre-
quency of tens among billions of blood cells. [ 29,30 ] The vast 
majority of the background cells (blood cells) contribute to 
not only challenges in enriching for the target cells (CTCs), 
but purity issues during downstream molecular analyses. [ 1 ] 
Attempts at increasing CTC concentrations by expanding 
them after isolation are hardened by viability issues. [ 30 ] Hence, 
the key aspects of any CTC isolation technology should be a 
high recovery rate without compromising on purity and via-
bility. [ 30 ] A plethora of microfl uidic technologies have risen to 
these challenges with promising results. With their help, scien-
tists are now analyzing complex fl uids such as blood in vitro, 
as a means to investigating noninvasive alternatives for cancer 
detection, patient prognosis and therapeutic monitoring. [ 15 ] 
 1.2.  The Use of Micro and Nanofl uidics for Studying CTCs 
 Microfl uidic devices have had a major impact on the fi eld 
of CTC research. [ 31 ] Such efforts have been facilitated by 
the automation of labor-intensive experimental processes 
involved in isolating and characterizing CTCs. As a conse-
quence, the microfl uidic fi eld has been gaining pace espe-
cially in the handling of rare cells. [ 30,32 ] Different materials 
ranging from traditional silicon and glass to elastomers 
have been used for making these devices. The use of poly-
dimethylsiloxane, an elastomer, has made rapid prototyping 
an easy and preferred method, leading to widespread use of 
microfl uidic technologies for investigating CTCs. [ 29,33 ] Their 
smaller dimensions allow precise manipulation of fl uid fl ow 
in the devices, translating to better control over the cells. The 
smaller volumes also demand lesser reagents. [ 33 ] Microfl u-
idics for CTC isolation gained popularity with the reporting 
of the CTC-chip. [ 21 ] Over the years, a large number of sim-
ilar and innovative microfl uidic platforms have come up, 
each exploiting specifi c properties of CTCs to separate them 
from blood cells. The different properties may be biological 
such as target antigens, or physical such as size, density, and 
deformity. [ 29,34 ] This review compares the two most widely-
used methodologies, namely affi nity-based (biological) and 
size-based (physical) techniques of CTC isolation. 
 1.3.  Methods of CTC Isolation in Microfl uidic Devices 
 Microfl uidic technologies are mainly categorized by their 
exploitation of CTCs’ distinctive (i) biochemical proper-
ties or (ii) biophysical properties. The former is based on the 
expression of cell surface markers, while the latter includes 
size, deformability, density, and electric charge. [ 35 ] For either 
of these strategies, it is imperative that developing an optimal 
CTC isolation method meet the following criteria: (i) high 
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recovery, (ii) high purity of CTCs by removal of contami-
nating blood cells, and (iii) high system throughput to ensure 
handling of large sample volumes as expected for clinical set-
tings. [ 30 ] Capture or retrieval of CTCs is followed by identi-
fi cation by immunocytochemical staining demonstrating 
positive signals for Cytokeratin(s) and the nuclear stain DAPI 
(4′,6-diamidino-2-phenylindole), with the absence of the leu-
kocyte marker CD45. [ 21 ] Although there are multiple methods 
in each category of isolation, in this review we will focus on 
two of the most prevalent methods for CTC isolation- affi nity, 
and size based or label-free isolation ( Figure  1 ). We will high-
light new progress and emerging technologies for each isola-
tion method. Furthermore, we will elucidate the advantages 
and disadvantages based on their downstream applications for 
studying subpopulations and heterogeneity, genomic charac-
terization, cell expansion, in vivo studies, and single cell anal-
ysis of CTCs. In this review, we will focus on highlighting the 
latest microfl uidic technologies that have been characterized 
and proven to work with clinical samples ( Table  1 ). 
 2.  Affi nity-Based Isolation of CTCs 
 2.1.  How It Works 
 Affi nity-based isolation, the main principle of technologies such 
as CellSearch and the CTC-chip, [ 21 ] make use of the affi nity of 
an antigen to its corresponding antibody. Antigens or surface 
markers present on the membrane of CTCs are targeted by 
specifi c antibodies that can be immobilized onto a solid sur-
face. [ 36 ] The antigens (and hence the cell) can grab on to the 
target antibodies under ideal conditions of affi nity-binding. The 
bound cells can then be separated and/or identifi ed for further 
assays, depending on their method of capture. The commonly 
used antigen for CTC capture is EpCAM, and is considered 
to be expressed by epithelial cancers. [ 15 ] While recent fi ndings 
have brought into question the utility of EpCAM in identi-
fying the aggressors, [ 37 ] it still remains the most widely adopted 
choice of capture antibodies. Combinations of antibodies are 
also being employed to widen the capture net. [ 38 ] 
 2.2.  Biomarker-Dependent Technologies 
for the Isolation of CTCs 
 The fi rst immuno-capture microfl uidic technology for CTCs, 
the CTC-chip [ 21 ] consists of a series of 100 µm tall microposts 
coated with antibodies against EpCAM, which can interro-
gate whole blood for capturing CTCs expressing the antigen. 
The novelty of this technology lay in its ability to capture 
CTCs from whole blood with high sensitivity and viability. [ 21 ] 
Following this, a number of technologies with varying degrees 
of sensitivity and purity were developed. The high-throughput 
microsampling unit, [ 39 ] cell enrichment and extraction (CEE) 
channel, [ 40 ] Herringbone chip or HB-chip, [ 33 ] the graphene 
oxide chip, [ 41 ] all performing EpCAM-based CTC cap-
ture, improved upon the above parameters ( Figure  2 ). The 
NanoVelcro CTC chip, another recently developed immuno-
capture device, makes use of nanosized structures coated with 
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EpCAM for CTC capture. [ 42,43 ] Other nanomaterial-based 
devices for CTC interrogation include the incorporation 
of carbon nanotubes, the porous nature of which provides 
a high surface area for cell interaction, [ 44,45 ] and the use of 
TiO 2 nanofi bres produced by electrospinning techniques for 
anti-EpCAM capture of CTCs. [ 46 ] The GEDI chip developed 
in 2010 [ 47 ] has a similar approach and enabled CTC isolation 
with an antibody against prostate specifi c membrane antigen 
(PSMA). They showed an improved purity over the CTC-chip 
and also opened the arena for achieving CTC capture with 
antibodies other than EpCAM. Different antibodies or anti-
body cocktails have since been explored to capture different 
populations that may have been otherwise missed. Galletti 
et al. demonstrated the use of anti-Her2 for studying CTCs 
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from breast and gastric cancer. [ 48 ] Yu et al. used a mixture 
of EpCAM, EGFR, and Her2 to capture CTCs from breast 
cancer. [ 12 ] Pecot et al. used an interesting approach wherein 
the cells are tagged with a cocktail of antibodies, followed 
by capture by functionalized microchannels. [ 38,40 ] Aptamers, 
which can be synthesized to specifi cally recognize target mol-
ecules on the surface of cells, have also been incorporated for 
CTC capture. [ 49 ] An example of a microfl uidic aptamer-based 
affi nity capture device was demonstrated by Sheng et al. for 
capture of colorectal CTCs from whole blood. [ 49 ] 
 Immuno-magnetic capture is also a popular method 
of affi nity isolation wherein magnetic beads coated with 
antibodies are made to bind to cells in order to separate 
CTCs from while leukocytes (WBCs). [ 1 ] MACS (magnetic 
activated cell sorter) is one such technology, that operates 
by separating cells bound to magnetic beads through a target 
antibody followed by purifi cation under a magnetic fi eld. [ 50 ] 
Magnetic nanoparticles are also used to label cancer cells 
through anti-EpCAM to separate them from blood cells with 
high effi ciency at a high fl ow rate of 10 mL h −1 . [ 51 ] Another 
novel immunological approach was developed by Shi and 
co-workers in which microbubbles enveloped with anti-
EpCAM were used for CTC isolation. [ 43 ] 
 Affi nity-based capture also holds negative selection 
under its umbrella, in which the target cells are made to pass 
through WBCs, are targeted by antibodies against CD45, [ 52,53 ] 
and/or CD15. [ 53 ] The advantage of negative selection lies in 
its capability of isolating CTCs that may or may not express 
epithelial markers. [ 53 ] This approach has been used in the 
CTC-iChip, [ 53 ] and by Wu et al. [ 54 ] Casavant et al. used mag-
netic beads coated with anti-CD45 as a means of depleting 
white blood cells as a precursor to CTC enrichment. [ 52 ] 
 Recently, the limitation of throughput for immuno-affi nity 
isolation of CTCs has been addressed by a number of devices 
operating at high fl ow rates. Of note are the demonstrations 
of the CTC-iChip [ 53 ] which is a combination of affi nity and 
size-based isolation, an integrated high-throughput device by 
Liu et al., [ 55 ] immunomagnetic isolation at 10 mL h −1 , [ 51 ] and 
the OncoBean Chip, a purely affi nity isolation device oper-
ating at 10 mL h −1 developed in our lab. [ 56 ] An in vivo CTC 
detection technology, the GILUPI CellCollector, employing 
anti-EpCAM to capture CTCs in venous blood fl ow is also an 
 Figure 1.  Isolation of circulating tumor cells (CTCs) is most popularly done by two strategies: affi nity-based and label-free methods. Affi nity-based 
techniques employ cell surface markers to capture CTCs, while label-free techniques exploit size differences between CTCs and blood cells. Both 
methods have their respective advantages and disadvantages, among them are high purity and the ability to capture physically/morphologically 
heterogeneous populations of CTCs by affi nity-based methods, and high-throughput and the ability to capture biologically heterogeneous populations 
of CTCs by label-free methods. Microfl uidic CTC isolation can also be used for a number of downstream applications for characterizing the CTCs.
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example of a system that demonstrates CTC isolation even 
under high physiological shear stresses (20 mL min −1 ) pre-
sent in the circulation. [ 57 ] 
 2.3.  Advantages of Immuno-Affi nity-Based Approaches 
 CTC enumeration, albeit a very important part of CTC 
studies, is only one aspect of the clinical utility of these 
cells. And while CTC numbers have been correlated to 
prognosis, [ 19 ] characterization of these cells is still an unmet 
and essential demand. With numerous technologies for CTC 
enrichment and enumeration in development, studies are now 
shifting gear toward addressing what these cells are capable 
of. With this in mind, a number of recent fi ndings have been 
published showing CTCs’ ability to metastasize, [ 58 ] their 
tumor forming potential, [ 12,59 ] their potential utility as agents 
showing drug response, [ 12 ] and their clonal heterogeneity. [ 13 ] 
 Table 1.  Summary of micro and nanofl uidic technologies for CTC isolation and analysis. 
Affi nity-based isolation
Technology Capture method Flow rate Capture effi ciency details Purity Clinical utility Reference
CTC-chip Affi nity (EpCAM) 1 mL h −1 >60% with different concentrations 
of NCI-H1650 cells (lung)
50% Tested with 116 patient samples 
(lung, prostate, pancreatic, breast 
and colon cancers)
 [ 21 ] 
HB-chip Affi nity (EpCAM) 1.2 mL h −1 92% with PC3 cells (prostate) 14% Tested with 15 prostate cancer 
patient samples
 [ 33 ] 
GEDI chip Affi nity (PSMA) 1 mL h −1 85% in blood with LNCaP cells 
(prostate)
68% Tested with 20 prostate cancer 
patient samples
 [ 47 ] 
NanoVelcro Chip Affi nity (EpCAM) 0.5 mL h −1 >80% with LNCaP, PC3, C4-2 cells 
(prostate)
– Tested with 40 prostate cancer 
patient samples
 [ 42 ] 
Graphene oxide chip Affi nity (EpCAM) 1 mL h −1 >85% with MCF7 cells (breast) – Tested with 20 patient samples 
(breast, pancreatic and lung cancer)
 [ 41 ] 
OncoBean Chip Affi nity (EpCAM) 10 mL h −1 >80% with H1650 (lung) and MCF7 
(breast) cancer cell lines
– Tested with 6 patient samples (lung, 
breast and pancreatic cancer)
 [ 56 ] 
Label-free isolation
Device Name Capture method Flow rate Capture effi ciency details Purity Clinical utility Reference
p-MOFF Size-based 
(Hydrodynamic)
0.6 mL min −1 93.75% with MCF-7 91.60% with 
MDA-MB-231
– Tested with 24 breast cancer patient 
samples
 [ 97 ] 








Tested with 5 metastatic lung cancer 
patient samples
 [ 87 ] 
N/A Size-based 
(Hydrodynamic)
3 mL h −1 >85% with MCF-7 – Tested with 20 metastatic lung 
cancer patient samples
 [ 60 ] 
SB microfi lter Size-based (Filter Pore 
type)
Gravity driven fl ow 83 ± 3% with MCF-7 78 ± 4% with 
MDA-MB-231
– Tested with 6 metastatic breast 
cancer mouse model and 1 
metastatic colorectal cancer patient 
samples
 [ 88 ] 
N/A Size-based (Filter Pore 
type)
>225 mL h −1 >90% with RT4, T24, HT-1080, 
LNCaP, MCF-7, SK-BR-3 and 
MDA-MB-231
– Tested with 51 patient samples 
(prostate, colorectal, breast and 
bladder cancer)
 [ 83 ] 
Vortex Chip Size-based 
(Hydrodynamic)
7.5 mL/20 min 15.9% A54816.8% OVCAR5 17.7% 
MCF-7 17.7% M395 18.2% PC3
57%–94% Tested with 12 patient samples 
(breast and lung cancer)
 [ 96 ] 
N/A Size-based (Centrifugal 
Force)
 3 mL whole blood 
in 20 s 
 (2400 rpm) 
61% with MCF-7 – Tested with 23 patient samples 
(lung and gastric cancer)
 [ 93 ] 
N/A Size-based (DEP) 10 mL h −1 70%–80% With MDA-MB-435 and 
MDA-MB-231
– Tested with late stage colon cancer 
patients
 [ 102 ] 
N/A Size-based 
(DC-Impedance)
13 µL min −1 88% with OVCAR-3 – Tested with 24 breast cancer 
patients samples









Tested with 10 patient samples 
(breast and lung cancer)
 [ 98 ] 
N/A Size-based 
(Hydrodynamic)
7.5 mL/10 min 87.6% with MCF-7 76.4% with T24 – Tested with 10 patient samples 
(breast and lung cancer)
 [ 99 ] 
N/A Size-based (tilted-angle 
standing surface acoustic 
waves (taSSAWs)





Tested with 3 metastatic breast 
cancer patients
 [ 72,73 ] 
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Baccelli et al. showed that CTCs are a diverse pool of cells, 
and may contain a certain population of metastasis initiating 
cells which would be the aggressive cells. [ 58 ] 
 Because of the principle of capture, affi nity-based iso-
lation offers very high specifi city of the recovered CTCs 
since the target CTCs are validated by the capture antigen 
in addition to identifi cation by immunostaining procedures. 
The method also enables recovery of an assorted pool of 
CTCs, regardless of morphological considerations such as 
size. Whilst many size-based technologies may capture CTCs 
with high yields, the wide variability of CTC sizes previously 
reported [ 10,29,60 ] makes the smaller CTCs highly probable to 
be missed in size-based techniques which are usually biased 
toward the larger cells. Affi nity-based methods can indis-
criminately capture such populations, and are also capable of 
doing the same without the need for preprocessing steps such 
as dilution or red blood cell lysis, invariably required by phys-
ical separation techniques. [ 60 ] The specifi city also allows for 
better downstream analysis which may have clinical utility. 
One such application was demonstrated by Maheswaran 
et al. who performed downstream sequencing studies on 
CTCs captured on an affi nity platform (the CTC-chip) from 
lung cancer patients. [ 23 ] 
 Affi nity capture also allows high purity of the recov-
ered CTCs. [ 47 ] Since these cells are rare, any downstream 
applications are dictated by the accompaniment of contami-
nating blood cells. The specifi city of CTC capture by affi nity 
techniques is also refl ected in the retained background cells. 
The targeted capture not only allows for low nonspecifi c 
retention but also washes away most red blood cells, elimi-
nating the need for red blood cell lysis as a precursor to blood 
analysis. The highly specifi c and pure CTC yield facilitated by 
 Figure 2.  Affi nity-based micro and nanofl uidic technologies for CTC isolation. A,B) The HB chip is designed to capture CTCs by enhancing mixing 
inside the chamber Reproduced with permission. [ 33 ] Copyright 2010, PNAS. C) The NanoVelcro chip showing nanostructures coated with antibody 
for cell capture Reproduced with permission. [ 42 ] Copyright 2013, Elsevier. D) Image of the fl ow dynamics in the GEDI chip that uses PSMA to capture 
CTCs Reproduced with permission. [ 47 ] Copyright 2009, Royal Society of Chemistry. E) The design of the graphene oxide chip showing gold nanoposts 
for CTC capture Reproduced with permission. [ 41 ] Copyright 2013, Nature Publishing Group. F) Radial fl ow OncoBean Chip showing antibody-coated 
microposts for CTC capture Reproduced with permission. [ 56 ] Copyright 2014, John Wiley and Sons.
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immuno-capture combined with the viability is also condu-
cive to CTC culture and expansion. [ 61 ] 
 In order to effi ciently study the diverse properties of 
CTCs, their isolation needs to be tailor-made to answer 
the relevant biological questions. Immuno-affi nity offers 
a beautiful platform for this purpose as antibody-based 
capture techniques can be customized to target different 
subpopulations of CTCs. A combination of antibodies con-
sisting of the traditional anti-EpCAM with another marker, 
or successive captures with the respective individual anti-
bodies can yield the desired populations. [ 38,62 ] For instance, 
Riethdorf et al. utilized HER2 as a target agent to identify 
CTCs among patients undergoing neoadjuvant treatment 
for a HER2 inhibitor. [ 8 ] Pecot et al. used an interesting 
cocktail of antibodies to target both epithelial cells and 
potential CTCs undergoing EMT. [ 38 ] Affi nity-based cap-
ture techniques are thus widely capable of specifi c tar-
geting of cell subpopulations, an area requiring deeper 
attention as more and more studies illuminate tumor cell 
heterogeneity. [ 14 ] 
 Affi nity-based methods also offer high utility with respect 
to capturing rare events such as CTC clusters. [ 13,33 ] These 
clusters may sometimes be larger than the detection range 
of physical separation techniques and/or may clog the chan-
nels. [ 63 ] CTC clusters are believed to have more metastasizing 
capability than single cells in the circulation. [ 13,64 ] Larger 
clusters containing a heterogeneous mix of cells may also be 
captured if some of the cells in the cluster express the target 
antigen, thereby achieving capture of potentially “unfamiliar” 
populations using “known” targets. Furthermore, the gen-
erally lower shear experienced by cells in immuno-affi nity 
capture [ 56 ] also enables collection of CTCs that are possibly 
circulating in conjunction with platelets. Platelets are believed 
to be implicated in metastasis and platelet-enveloped CTCs 
may be important in disease progression as they are able to 
evade immune surveillance. [ 13,65–67 ] 
 2.4.  Disadvantages of Affi nity-Based Approaches 
 Traditionally preferred for CTC isolation, [ 15 ] affi nity 
methods have validated their utility in a number of CTC 
analyses studies. However, they suffer from a few limita-
tions. Throughput is a major concern with antibody-based 
CTC recovery chips such as the CTC-chip and HB-chip. [ 53 ] 
This is due to the limited shear conditions under which 
affi nity binding occurs. [ 56 ] Microfl uidic fl ow-based affi nity 
capture requires optimal velocity and shear conditions 
for antibody–antigen binding. [ 21,36 ] A very high shear may 
disrupt any bonds if formed, while a very low shear is con-
ducive to nonspecifi c cell binding. [ 56 ] An optimal binding 
condition would provide adequate capture of target cells, 
with minimal amount of blood cells retained; in other words, 
a high effi ciency with minimal contamination. These optimal 
conditions limit the velocity of fl ow during capture. The 
CTC-chip and its successors operating on similar principles 
therefore had an operating fl ow rate of 1–3 mL h −1 . [ 56 ] In the 
CTC-chip itself, increasing the fl ow rate from 1 to 3 mL h −1 
diminished the capture effi ciency. [ 21 ] This limits the blood 
volume that can be analyzed due to the time constraints it 
places on the experiments. Of late, a number of technologies 
have overcome the throughput limitation by introducing 
novel designs to circumvent the issue of optimal binding 
conditions. [ 56 ] 
 EMT transition, a process in which cells lose their 
epithelial characteristics and become more mesenchymal, 
is believed to be an important process hampering the study 
of CTCs on the basis of EpCAM alone. [ 10 ] As these cells 
undergo the change, their EpCAM expression decreases, and 
they may be missed by EpCAM targeted capture. [ 10,68 ] These 
EMT-undergoing cells are believed to be important players 
in metastasis [ 68 ] and may be able to provide useful informa-
tion about the dissemination of tumor cells. [ 10 ] Combinations 
of antibodies are therefore being employed to capture not 
only epithelial cells, but also the mesenchymal ones. [ 38 ] 
 Many microfl uidic affi nity-based technologies employ 
surface modifi cations for antibody conjugation and immobili-
zation. [ 21 ] This poses problems as many of the bonds are irre-
versible and cannot be easily degraded and/or may affect the 
viability of these rare cells themselves in the process. [ 69 ] Sub-
sequent assays such as single cell analysis and CTC derived 
xenografts may not be feasible in such cases due to cell 
release diffi culties. [ 69 ] Many genetic analyses performed on 
CTCs thus depend on nucleic acid extraction from the pool 
of cells captured on these devices, which may create back-
ground noise as the captured populations contain impurities 
such as blood cells. [ 1 ] 
 3.  Label-Free Isolation of CTCs 
 3.1.  How It Works 
 The use of physical properties allows a label-free isolation, 
aimed to overcome biased cell selection using biological-
based separation methods. This approach allows the isola-
tion of intact cells without stressing their plasma membrane 
through antibody binding, which is a vital aspect for further 
downstream characterization of CTCs. This method tends 
to exploit the size differences among CTCs and other blood 
components. More specifi cally, CTCs have been shown to 
have a diameter of 13–25 µm in diameter, [ 32 ] larger than 
the rest of the blood cells such as leukocytes with diameter 
ranges from 8 to 11 µm, [ 70 ] and red blood cells (RBCs) with 
diameters in the range of 5–9 µm. [ 71 ] Label-free approaches 
can be classifi ed into three main categories- fi ltration, hydro-
dynamic chromatography, and dielectrophoresis (DEP). In 
addition, other novel methods exploiting the physical prop-
erties of CTCs including acoustic separation have also been 
recently developed. [ 72–74 ] 
 3.2.  Biomarker-Independent Technologies for the 
Isolation of CTCs 
 Compared to immuno-affi nity-based approaches, the bio-
marker-independent CTC isolation technologies are still 
evolving. While many of these have been optimized with 
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cancer cell lines, few have been validated with clinical spec-
imens. The use of cancer cell lines as a CTC model makes 
an ideal model for the optimization of a new technology. 
However, cell lines do not represent the heterogeneous mor-
phology found in clinical specimens. [ 75 ] Some subpopulations 
of CTCs will indeed be more deformable and smaller than 
cancer cell lines. Therefore, using cell lines to optimize new 
technologies may not serve as a true test of effi ciency as their 
clinical utility will only be determined by testing clinical sam-
ples. [ 76 ] Here, we summarize the recent label-free microfl uidic 
technologies that have been (i) characterized using cancer 
cell lines and (ii) clinically proven to work by isolating CTCs 
from patient samples over the past fi ve years ( Figure  3 ). 
 3.2.1.  Filtration Methods 
 Membrane-based fi ltration is one of the fi rst methods used 
for isolating CTCs, being a relatively straightforward and 
low-cost technique. This method captures target cells using 
constrictions based on cell size and deformability. [ 76 ] Most 
of the reported membranes have pore sizes around 7–8 µm 
 Figure 3.  Label-free micro and nanofl uidic technologies for CTC isolation. A) The parallel multiorifi ce fl ow fractionation (p-MOFF) device allows 
label-free isolation of CTCs by inertial forces through a series of contraction and expansion structures. Reproduced with permission. [ 97 ] Copyright 
2013, Elsevier. B) Centrifugal microfl uidic device uses a track-etched polycarbonate (PC) membrane fi lter to isolate CTCs based on size. Reproduced 
with permission. [ 93 ] Copyright 2014, American Chemical Society. C) The separable bilayer (SB) microfi lter uses biocompatible polymer parylene-C to 
enrich CTCs. Reproduced with permission. [ 88 ] Copyright 2014, the authors. D) The use of two polyelectrolytic gel electrodes under low DC voltages 
allows the DC impedance-based microcytometer to isolate CTCs. Reproduced with permission. [ 103 ] Copyright 2013, Royal Society of Chemistry. 
E) The ultrahigh-throughput spiral takes advantages of inertial focusing inside the device to isolate CTCs. Reproduced with permission. [ 99 ] Copyright 
2014, Royal Society of Chemistry. F) Vortex Chip uses microscale vortices and inertial focusing for extraction of CTCs from blood. Reproduced with 
permission. [ 96 ] Copyright 2013, Royal Society of Chemistry.
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diameter, with few reporting on membranes with pore size 
diameters up to 11  µm. [ 77 ] Vona et al. proposed ISET 
(isolation by size of epithelial tumor cells), a commercially 
available technology that uses a polycarbonate membrane-
fi lter. [ 78 ] This is a fi ltration method that uses 8 µm cylindrical 
pores to capture CTCs. However, its large variability in CTC 
capture effi ciency and low purity caused by membrane clog-
ging left opportunities for further improvement. Integrating 
microfabricated fi ltration membranes into microfl uidic 
devices has since emerged as an optimized approach for 
CTC separation. Materials such as polycarbonate, [ 79–81 ] par-
ylene-C, [ 82–84 ] nickel, [ 85 ] and silicon [ 86 ] have demonstrated to 
provide the appropriate membrane surface area and porosity 
to enhance CTC capture. 
 In 2010, Lin et al. published one of the fi rst label-free 
methods to be tested using clinical samples. [ 83 ] With a total 
of 57 human samples from various cancer types, this parylene 
membrane microfi lter identifi ed CTCs in 51 out of 57 patients 
compared to only 26 patients with the CellSearch method. 
Tan et al. published a label-free biochip that uses physical 
structures or pillars to trap single cells without having cell 
buildup. [ 87 ] Lim et al. developed a silicon microsieve that con-
tains a dense array of pores to isolate CTCs at a fl ow rate 
of 1 mL min −1 . [ 86 ] Zhou et al. designed a device that aims 
for the fi lter-based capture of viable cells with the use of a 
design that incorporates a low mechanical stress, termed the 
separable bilayer (SB) microfi lter. [ 88 ] The high viability of 
enriched CTCs using the SB microfi lter allows for functional 
analysis and on-chip expansion of CTCs, further discussed in 
the next section of this review. 
 3.2.2.  Hydrodynamic Methods 
 Hydrodynamic-based approaches have shown the highest 
throughput capability. [ 77 ] Recently, inertial migration of par-
ticles has been introduced and applied in various studies to 
achieve high throughput separation based on particle size. [ 89 ] 
Briefl y, the particles migrate and are focused in microchan-
nels due to the equilibrium of two inertial lift forces which 
act on the particles in opposite directions- shear gradient lift 
force and wall lift force. [ 89 ] Some other technologies exploit 
a secondary fl ow called Dean fl ow that takes place in cur-
vilinear channels. [ 90 ] In addition, hydrophoresis is another 
approach that makes use of rotational fl ow for separating 
particles based on size. [ 91 ] Another approach, termed deter-
ministic lateral displacement, in which microposts are strate-
gically placed to divide the fl ow into several laminar streams, 
are also used for separation of CTCs from blood cells. [ 92 ] 
Regardless of the type of hydrodynamic-based technologies, 
the goal is to impart different fl ow velocities based on cell 
size differences to separate the target cells with high effi -
ciency. Lee et al. developed a lab-on-a disc platform that uti-
lizes centrifugal force to rapidly transfer unprocessed whole 
blood samples from one chamber to another. [ 93 ] The selective 
isolation of CTCs was achieved through the use of a com-
mercially available track-etched polycarbonate membrane 
fi lter on a lab-on-a-disc system. Hou et al. developed a spiral 
microchannel for separation of CTCs using centrifugal forces, 
a principle known as Dean Flow Fractionation. [ 60 ] Using this 
device, they were able to detect a subpopulation of CTCs 
that were positive for CD133, a phenotypic marker charac-
teristic of stem-like behavior in lung cancer cells. [ 94 ] Further-
more, this device was the fi rst inertial device to demonstrate 
the capacity to process blood samples with a high hemato-
crit. Our group also demonstrated theoretical investigation 
of inertial separation of CTCs using cascaded spiral microfl u-
idics. [ 95 ] Sollier et al. developed the Vortex Chip, which uses 
microscale vortices and inertial focusing to isolate CTCs. [ 96 ] 
Hyun et al. developed a parallel multiorifi ce fl ow fractiona-
tion (p-MOFF) device in which contraction/expansion micro-
channels were placed in a parallel confi guration for CTC 
separation. [ 97 ] This device was shown to use inertial forces 
to isolate CTCs from 24 breast cancer patients at a high 
throughput. [ 97 ] Warkiani et al. developed the trapezoid chip, 
which uses a trapezoidal design and exploits Dean forces and 
lift forces to isolate CTCs. [ 98 ] More recently, Warkiani et al. 
reported an ultrahigh-throughput spiral device [ 99 ] consisting 
of three stacked spiral microfl uidic chips with two inlets 
and two outlets, in which the combination of the inertial 
and Dean forces focuses the cells at certain equilibrium posi-
tions of the channel cross-section. Khoo et al. published an 
improved version of this technology with clinical validation 
using a large number of clinical samples, and also performed 
downstream immunophenotyping and molecular analyses 
from isolated CTCs, [ 100 ] further discussed in the next section. 
 3.2.3.  Dielectrophoresis Methods 
 DEP methods are used for isolating CTCs based on cell 
membrane and cell dielectric properties. Using this approach 
CTCs are generally separated by their response to nonuniform 
electrical fi elds, since the polarizability of a cell relies on its 
composition, morphology and the frequency of the applied 
electric fi eld. [ 101 ] Therefore, using DEP-based devices allows 
the identifi cation of cells with different phenotypes. How-
ever, compared to the two previously described approaches, 
DEP-based technologies do not show high selectivity and 
have low throughputs (<1 mL h −1 ). [ 76 ] 
 Shim et al. used a continuous fl ow microfl uidic pro-
cessing chamber into which CTCs are isolated from clinical 
samples using a combination of DEP, sedimentation, and 
hydro dynamic lift forces. [ 102 ] Choi et al. designed a novel 
DC (direct current) impedance-based microcytometer that 
detects changes in DC impedance and exploits size differ-
ences between CTCs and blood cells. [ 103 ] 
 3.3.  Advantages of Label-Free Approaches 
 Physical CTC separation methods have the potential to 
address the shortcomings involved in biological marker-based 
separation methods. Overcoming biased cell selection using 
molecular markers permits heterogeneity studies on CTCs, 
where different subpopulations can be analyzed. As previ-
ously mentioned, CTCs that have undergone EMT are asso-
ciated with a loss of expression for epithelial markers, such 
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as EpCAM and Cytokeratin. As a result, the most aggressive 
cancer cells could potentially be the least likely to be cap-
tured and identifi ed using EpCAM-based technologies. [ 32,38 ] 
 Isolated CTCs can be collected without compromising 
cell viability or gene expression, which in turn enables their 
molecular characterization. For instance, Shim et al. used con-
tinuous fl ow dielectrophoretic fi eld fl ow fractionation method 
and also performed molecular studies on isolated CTCs. [ 102 ] 
For a colon primary tumor, 10% of the stained cells had the 
KRAS G13D mutation, which also refl ected the number of 
cells that were stained positive for Cytokeratin. Warkiani et al. 
performed DNA fl uorescence in situ hybridization (FISH) 
to evaluate the HER2 status of isolated CTCs from breast 
cancer patients using their trapezoid chip. [ 98,99 ] Their results 
showed that the presence of HER2+ CTCs varied across sam-
ples and was also observed in samples derived from patients 
with HER2- tumors (2 out of 5). A later spiral technology by 
Warkiani et al. characterized CTCs that were isolated from 
lung and breast cancer patients by immunophenotyping using 
cell markers such as Pan-cytokeratin, CD45, CD44, CD24, and 
EpCAM, FISH for EML4-ALK fusion or targeted somatic 
mutation analysis. [ 99 ] They also demonstrated the ability to 
fi nd matching mutations of the EGFR gene in CTCs, cell-free 
DNA, and tumor biopsy specimens. [ 100 ] 
 Unlike most immuno-affi nity-based isolation systems 
which only allow on-chip growth of CTCs [ 61 ] due to diffi cul-
ties in postseparation retrieval, [ 69 ] inertial-based technologies 
simplify CTC culture by using off-chip standard cell culture 
techniques since cells can be recovered in suspension. This 
advantage gives rise to multiple CTC expansion approaches, 
such as the use of extracellular matrix (matrigel or collagen) 
for CTCs growth or a 3D culture system. [ 61 ] Sollier et al. 
showed that A549 cells processed with the Vortex Chip and 
collected in a well-plate proliferate over 3 days. [ 96 ] Similarly 
Hou et al. used their device to demonstrate this advantage by 
successfully culturing sorted MCF-7 cells for 5 days. [ 60 ] More-
over, they also show the retrieval of intact MCF-7 cell clusters. 
Despite the high throughput of the label-free devices, these 
technologies are still able to preserve cell clusters, which are 
of greater interest to study the metastatic ability of CTCs. [ 13,104 ] 
 In vivo application of label-free technologies is still very 
limited. In one study Zhou et al. used their SB microfi lter 
device to perform the only in vivo study currently published 
using a label-free microfl uidic device. [ 88 ] This group demon-
strated capture and expansion of CTCs originated from two 
mouse model systems from 4T1 and 4T07 cells. They dem-
onstrated tumor formation after injection of 4T1 CTCs and 
4T07 CTCs into BALB/C mice. Their study also showed 
similar tumorigenicity for both CTCs recovered by the SB 
microfi lter. 
 3.4.  Disadvantages of Label-Free Approaches 
 Although on average CTCs are shown to be larger than 
leukocytes, there is a signifi cant overlap in the size of CTCs 
and leukocytes that may hinder label-free separation efforts. 
The FDA-approved CellSearch system has detected CTCs 
with cell diameters ≈4 µm. [ 25 ] Marinnucci et al. also reported 
fi ndings on CTCs that were the same size or smaller than leu-
kocytes. [ 105 ] This variability in size can cause the loss of CTCs 
or, to overcome such problem, low sample purity. Although 
greatly studied, fi lter-based approaches encounter clogging 
diffi culties when processing large sample volumes. [ 106 ] This 
results in fl ow rate discrepancies, which could endanger 
important performance characteristics ranging from device 
reproducibility to cell viability for postprocessing analysis. 
Regarding the use of DEP, one concern is the effect on 
the viability of CTCs due to the generation of gases like 
hydrogen and oxygen. Moreover, elevated temperatures may 
also affect cell viability. [ 107 ] 
 4.  The Future 
 The fi eld of microfl uidics and CTCs is rapidly evolving. In 
fact, last year the journal Lab on a Chip published a complete 
CTC-themed issue that highlights some of the new technolo-
gies along with review papers targeting different aspects, 
both technical and clinical. [ 108 ] Both affi nity and size-based 
methods of CTC isolation need dramatic improvements 
to their systems to enable highly effi cient CTC recovery. [ 1 ] 
Affi nity isolations have the potential to provide key informa-
tion that may be missed by size-based techniques as outlined 
in their advantages above. Refi nements such as increasing 
throughputs, targeting multiple populations with the use of 
multiple antibodies may be the important steps needed to 
further improve these technologies. Use of novel materials 
and reversible conjugation of antibodies that may enable 
CTC release will offer more robust CTC analysis modules, as 
these CTCs can then be utilized for downstream assays. [ 69,109 ] 
Using immuno-capture methods, different populations of 
CTCs can be segregated for further analysis that may be able 
to identify tumorigenic CTCs, such as xenograft studies. [ 110 ] 
As for label-free technologies, their future is driven by 
exploiting the physical differences between CTCs and leuko-
cytes, with the goal of achieving selective separation of CTCs. 
For example, cell deformability can be combined with CTC 
size properties to develop new label-free technologies. [ 76 ] 
Regardless of the technological approach, emerging technol-
ogies should not compromise throughput or sensitivity, while 
still targeting heterogeneous CTCs. 
 Past the improvement upon current microfl uidic tech-
nologies, we predict an increase in effort on the molecular 
understanding of CTCs, encompassing multiple downstream 
analyses that advances personalized treatment. Comprehen-
sive investigation of CTCs is hampered by their low numbers, 
making this one of the biggest challenges in this fi eld. [ 30 ] For 
better understanding of CTCs, we expect to see an increase in 
technologies that not only aim for the isolation of such cells, 
but also to perform in situ expansion on such devices. For 
example, Zhang et al. expanded CTCs from early lung cancer 
patients using a 3D coculture device that used cancer associ-
ated fi broblasts and a combination of collagen and matrigel 
to resemble the tumor microenvironment. [ 61 ] Moreover, we 
predict an increase of label-free methods for straightfor-
ward retrieval of CTCs from microfl uidic chips, leading to 
ex vivo expansion. Recently, several groups have successfully 
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performed ex vivo expansion of CTCs from breast cancer [ 111 ] 
and from colon cancer. [ 112 ] Overcoming the limitation of low 
numbers of CTCs by expanding them will allow for pheno-
typic and genomic characterization of CTCs, which in turn 
will lead to personalized treatment strategies. The establish-
ment of cell lines from cancer patients could guide the course 
of drug therapy at an individual level to ensure optimal treat-
ment outcome. 
 Heterogeneity among CTCs makes their isolation and 
characterization a challenging task. The molecular characteri-
zation of CTCs has exposed information on the genotype and 
phenotype of these tumor cells and demonstrated a striking 
heterogeneity of CTCs. [ 113 ] Thus, the present setback is the 
identifi cation of the functional properties of the different 
CTC subsets. This could be achieved through the use of func-
tional assays that reveal the biology of CTCs, with particular 
emphasis on the discovery of the most aggressive subset of 
CTCs. At present, such assays are limited by the very low con-
centration and yield of CTCs. Single cell studies could serve 
as an essential tool to assess the heterogeneity among CTCs. 
The study of single CTCs by their molecular characterization 
provides high clinical relevance by potentially aiding in early 
cancer detection and revealing new therapeutic targets for 
personalized medicine. [ 114,115 ] 
 While CTC enumeration has shown tremendous potential 
in terms of clinical utility, [ 116 ] researchers are now exploring 
their validity as more than just an enumerable measure of 
disease intensity or spread. The prognostic and diagnostic 
utilities of CTCs are now an area of extensive focus through 
analysis of gene expression profi les, [ 117 ] single cell analysis, [ 11 ] 
RNA and DNA studies, [ 2,23 ] and cytogenetics to detect gene 
amplifi cations or rearrangements. [ 118,119 ] Examining epige-
netic modifi cations and their after effects on the metastatic 
cascade may be a useful tool for determining therapeutic effi -
cacy. Chimonidou et al. analyzed CTCs and cell-free DNA 
in breast cancer for methylation of a tumor suppressor gene 
SOX17 promoter. [ 120 ] In another study of breast cancer, 
methylation of a metastasis suppressor gene was studied in 
primary tumor and CTCs, and the authors investigated its 
effect on survival. [ 121 ] Whilst the rarity of CTCs offers chal-
lenges in enrichment and downstream assay feasibilities, 
cell free DNA suffer from similar limitations with respect 
to available amounts. [ 122 ] Malara et al. identifi ed CTC sub-
populations that are enriched for methylated DNA using 
folate receptors. Methylation of cancer cells is believed to be 
implicated in metastasis, and the authors found that patients 
with high methylation of CTCs had a risk of relapse. [ 122 ] 
Albeit CTC enumeration has seized attention as a possible 
endpoint in clinical trials due to their prognostic utility, [ 8 ] a 
comprehensive analysis of the genome and epigenome will 
likely compliment traditional diagnostic methods and open 
the arena for more frequent patient monitoring, leading to 
timely decision making. This also has the potential to circum-
vent invasive tissue biopsies. [ 21 ] CTCs also offer a means of 
personalized therapeutics through their tumorigenic capabili-
ties. [ 110 ] CTC expansion on in vitro microfl uidic models, one 
of which has recently been demonstrated by our group [ 61 ] 
propose a method for testing of drugs or drug combina-
tions, [ 107,110 ] which can be used to make quicker decisions 
for therapeutic management. Resistance to treatment can be 
monitored similarly by analyzing CTCs. [ 23 ] The idea that all 
of the above could possibly be accomplished through veni-
puncture, a relatively low discomfort means to achieving a 
higher end, in a fi eld as vast and challenging as cancer man-
agement, is both an exciting and formidable notion. The 
future of CTCs thus looks promising toward patient-specifi c 
tumor monitoring. 
 5.  Conclusion: Who Wins? 
 Affi nity and size-based methods have both shown great promise 
in CTC isolation, with each offering differing perspectives and 
newer insights into the fi eld. With the advent of new technolo-
gies, each aims to overcome the pitfalls of its predecessor with 
respect to sensitivity, specifi city, throughput and/or purity. With 
a plethora of platforms now available for reliable CTC isola-
tion, the question remains as to which methodology is superior. 
While this does not have a simple answer, a better question 
yet would be to ask which methodology would most suit the 
end user requirements based on the biological questions being 
asked. An ideal CTC extraction method would be a combina-
tion of both techniques- an affi nity-based enrichment followed 
by interrogation of the remaining cells by a size-based method, 
or vice versa. This would obviate the likely pitfalls of any one 
technique and potentially offer the versatility of targeted cap-
ture through affi nity isolation, in addition to addressing bio-
logical heterogeneity through size-based retrieval of CTCs. 
Indeed, a few researchers have shown such promising combi-
nation methods, most notably the CTC-iChip by Ozkumur et 
al., which provides positive selection and negative selection 
modules for CTC interrogations. [ 53 ] This device incorporates 
size-based separation and immunomagnetic selection (positive 
or negative). [ 53 ] The CTC-iChip is high throughput (8 mL h −1 ) 
with high capture effi ciency (97%) for both positive and nega-
tive settings. Another technology by Liu et al. offers an integra-
tion of deterministic lateral displacement along with affi nity 
capture. [ 55 ] More recently, an integrated device has been devel-
oped in our lab that combines inertial sorting with immuno-
magnetic capture, which provides yields of very high purity 
enabling molecular analysis of the enriched CTCs. [ 123 ] Such 
integrated techniques open up opportunities for downstream 
analyses, especially in studying the tumorigenicity or metastatic 
capabilities of CTCs. And while the answer is not yet obvious, 
we do not foresee either of the techniques becoming obsolete 
since they each bring their own fl avors to the table. 
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